NEFERTITI SIGNED
A Novel Eco-Friendly, dually Efficient and Resistance-free Treatment of vaginITIs
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NEFERTITI project word cloud
Explore the words cloud of the NEFERTITI project. It provides you a very rough idea of what is the project "NEFERTITI" about.
Project "NEFERTITI" data sheet
The following table provides information about the project.
| Coordinator |
GEDEA BIOTECH AB
Organization address contact info |
| Coordinator Country | Sweden [SE] |
| Total cost | 4˙186˙716 € |
| EC max contribution | 2˙991˙774 € (71%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-EIC-FTI-2018-2020 |
| Funding Scheme | IA |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-01-01 to 2021-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | GEDEA BIOTECH AB | SE (LUND) | coordinator | 1˙970˙073.00 |
| 2 | LINK MEDICAL RESEARCH AS | NO (OSLO) | participant | 818˙125.00 |
| 3 | NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST | UK (Nottingham) | participant | 203˙576.00 |
Map
Project objective
Bacterial vaginosis (BV) and vulvovaginal candidiasis (VCC) are common vaginal infections caused by Gardnerella and other anaerobic bacteria. or by Candida fungi. The infection can occur once - the acute form - or recur repeatedly over the course of a year. About 68m women in Europe and the US are infected each year. They cause intense physical discomfort, adversely affects quality of life and have heavy socioeconomic costs.
Many women opt to self-treat with non-prescription over-the-counter antifungals which fail because the causative microorganism has not been properly identified. Antibiotics for BV are encountering increasing levels of drug resistance. Combination of misdiagnosis, misuse, non-compliance, overconsumption leads to low efficacy and high recurrence rates for both VVC and BV.
NEFERTITI FTI will demonstrate in clinical trials a pessary based on glucono-δ-lactone –trademarked as pHyph - as a highly effective cure for acute and recurrent BV and VVC, and as a far better alternative to antibiotics or antifungals. pHyph restores the vaginal mucosa to pH4 and disrupts Candida biofilms, promotes the proliferation of natural and protective aerobic lactobacilli, and displaces Gardnerella and other anaerobic pathogenic bacteria. pHyph is a single solution for both pathogens and infections, and with both curative and protective effects, and does not trigger drug resistance in the microbiome. These features are unmatched by any other product on the market – whether as over the counter or prescribed.
NEFERTITI FTI will also develop a post-project business plan for the rapid scale up of production and commercialisation of pHyph in Europe in 2022 as an over-the-counter product into a market for BV and VVC treatments worth €1.7bn in 2022 and will be commercialised through a major drug distributor. The same plan will also mark the regulatory steps and commercial partners needed for pHyph to reach the US market in 2024.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEFERTITI" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEFERTITI" are provided by the European Opendata Portal: CORDIS opendata.